Skip to main content

Table 1 Demographics and clinical scores of participants

From: A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson’s disease using an ambulatory monitor

  PwPa Controlsa
Number 228 157
Gender 35% F: 65% M 61% F: 39% M
Age 71 (9.7) 69.6 (8.7)
Disease duration 6.0 (6.0) n/a
Unified Parkinson’s Disease rating scale
 Part I 10.0 (8.0) n/a
 Part II 11.0 (9.0) n/a
 Part III (“ON”) 36.0 (18.0) n/a
 Part IV 4.5 (6.0) n/a
 Total 62.5 (29.3) n/a
Levodopa Equivalent Daily Dose 675 (500) n/a
Parkinson’s Disease Questionnaire 28 (29) n/a
Median Dyskinesia Score 2.1 (3.7) 2.6 (2.8)
Adjusted median Dyskinesia Score 1.3 (2.5) 1.5 (2.2)
Median Bradykinesia Score 25 (9.6) 22.0 (2.8)
Active median Bradykinesia score 23.9 (7.8) 21.4 (3.2)
  1. aValues are mean and standard deviation (in parenthesis) of each variable from PwP and Control subjects